Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Canrenone is a steroidal antimineralocorticoid of the spirolactone group and an active metabolite of spironolactone. It acts as a competitive antagonist at the mineralocorticoid (aldosterone) receptor in the distal renal tubule, leading to increased sodium and water excretion while reducing potassium excretion. Canrenone is used primarily as a diuretic for conditions such as primary hyperaldosteronism, edematous states due to secondary hyperaldosteronism (e.g., heart failure), hepatic diseases, hypertension, and refractory edema associated with heart failure. It has also been found effective in treating hirsutism in women. Compared to spironolactone, canrenone is more potent as an antimineralocorticoid but less potent as an antiandrogen[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on canrenone.